Tivic Health Q3 revenue down 41% YoY to $282K; gross profit up 71% to $108K

Valion Bio, Inc.

2023-Q3 EPS reported -$10.60 vs consensus -$121.38 ▲ beat (+91.3%)

Net loss of $1.8M narrowed from $2.6M in Q3 2022; operating expenses fell 30% to $1.9M.
Gross margin improved to 38% from 13% YoY on price increases and supply-chain optimization.
Cash and equivalents totaled $5.2M as of Sept 30, 2023.
Announced partnerships with InStep Health and Amerisource Bergen; NASDAQ compliance regained after reverse stock split.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Valion Bio, Inc. reported the third quarter 2023 ended September 30, 2023 results: revenue $282 thousand.

Period: the third quarter 2023 ended September 30, 2023
Revenue: $282 thousand
Result: reported results

Exact text from the filing

medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 (“Q3 2023”). Third Quarter 2023 Financial Highlights • Revenue for Q3 2023 was $282 thousand, compared to $161 thousand for Q2 2023 and $477 thousand in Q3 2022. • Gross profit was $108 thousand, compared to $63 thousand in Q3 2022, an increase of 71%. • Gross Margin of

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-063735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.